The 2024 International Myeloma Society Annual Meeting was a groundbreaking event that showcased the latest advancements in ...

Jeffrey Wong, MD, discusses findings on the use of Cu 64 anti-CEA M5A as a PET imaging agent for advanced rectal cancer presented at the 2024 American Society for Radiation Oncology Annual Meeting.

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...

Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it ...

In an interview with Targeted Oncology, Jeffrey Wong, MD, discussed the potential and future directions of Cu 64 anti-CEA M5A ...

On September 3, OBX-115, a novel TIL therapy, was granted FDA regenerative medicine advanced therapy (RMAT) designation in ...

During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, surveyed how newer regimens influence a patient case of a ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Evidence suggests that extranodal extension on radiological imaging is a negative prognostic factor in head and neck cancer, ...

In an interview, Jeffrey Wong, MD, and Anthony Stein, MD, provided an in-depth discussion on a phase 2 trial of total marrow ...

During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to ...

Results from cohort 2 of the TROPHY-U-01 study showed that sacitizumab govitecan led to rapid responses in patients with ...